 |
BEIJING, September 11, 2012 /PRNewswire-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has obtained State Food and Drug Administration approval for DHR-CPAP-C5, one of Dehaier's major proprietary homecare medical devices. The period of validity for the SFDA approval is four years.
Continuous Positive Airway Pressure (CPAP) has become the first line of treatment for Obstructive Sleep Apnea Syndrome (OSAS) and for some forms of central sleep apnea. CPAP works by creating a pneumatic splint for the upper airway. A flow generator sends pressurized air through air tubing and a mask (usually a nasal mask) and through the nose to the upper airway. The pressurized air prevents the soft tissues of the upper airway from narrowing and collapsing. For proper CPAP treatment, patient can set high enough flow generator pressures to prevent apneas and hypopneas during all sleep stages and in all sleep positions. The SFDA approval indicated that DHR-CPAP-C5 has met the national health and safety standards and it will be launched in China soon.
Dehaier is committed to offering all-in-one solution for diagnosis, treatment and assessment of Obstructive Sleep Apnea Syndrome (OSAS). Currently, DHR-998 (used for diagnosis and treatment evaluation) has been put into the international market upon the receive of the CE Mark in 2011. Dehaier will continue to strengthen the domestic marketing effort for its high margin, proprietary homecare medical products and at the same time, explore new business model and strategic partnership.
"We are excited about the recent SFDA approval for DHR-CPAP-C5 which is another important step towards providing complete solution to fight sleep disorders." Commented by Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical, "Developing and expanding the market share of homecare medical equipment has become one of the Dehaier's critical business strategies because we believe in the tremendous growth potential in Chinese homecare medical market. With great efforts on R&D, product upgrade, diversification of product mix and expansion of patents, Dehaier is well prepared to not only educate the Chinese consumer about the homecare concept, but also serve the upcoming explosive demand for homecare medical equipment. We will seize any chance to become one of leading players in this promising market."
About Dehaier Medical Systems Ltd.
Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier's technology is based on six patents, nine software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn
Forward-looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the SFDA approval for DHR-CPAP-C5. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact Us
Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn
Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn
